Table 3.
Most common grade 3 to 4 adverse events analyzed in the pairwise meta-analyses
| Adverse event subgroup | No. of patients with grade 3-4 adverse events | Overall RR | 95% CI | P | |
|---|---|---|---|---|---|
| ET | CT | ||||
| Anemia | |||||
| BOR | 280 | 240 | 1.124 | 0.946-1.335 | .184 |
| IMiD | 208 | 252 | 0.843 | 0.659-1.079 | .175 |
| Thrombocytopenia | |||||
| BOR | 734 | 482 | 1.147 | 0.867-1.516 | .337 |
| IMiD | 277 | 197 | 1.594 | 1.059-2.397 | .025 |
| Neutropenia | |||||
| BOR | 461 | 251 | 1.672 | 1.198-2.334 | .003 |
| IMiD | 479 | 462 | 1.023 | 0.807-1.296 | .851 |
| Peripheral neuropathy | |||||
| BOR | 117 | 127 | 0.686 | 0.425-1.107 | .123 |
| IMiD | 60 | 36 | 1.118 | 0.527-2.374 | .771 |
| Fatigue | |||||
| BOR | 196 | 122 | 1.717 | 1.031-2.861 | .038 |
| IMiD | 80 | 65 | 1.224 | 0.890-1.683 | .213 |
| Diarrhea | |||||
| BOR | 199 | 119 | 1.190 | 0.636-2.224 | .586 |
| IMiD | 55 | 39 | 1.379 | 0.919-2.070 | .121 |
| Serious adverse event | |||||
| BOR | 870 | 679 | 1.219 | 1.083-1.372 | .001 |
| IMiD | 668 | 621 | 1.086 | 1.000-1.180 | .050 |
BOR, bortezomib; CT, conventional therapy; ET, experimental therapy.